PMID- 22838733
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20211021
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 14
IP  - 4
DP  - 2012 Jul 27
TI  - Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid 
      arthritis.
PG  - R175
LID - 10.1186/ar3928 [doi]
AB  - INTRODUCTION: The treatment of rheumatoid arthritis (RA) patients with anti-tumor 
      necrosis factor alpha (TNFalpha) biological drugs has dramatically improved the 
      prognosis of these patients. However, a third of the treated patients do not 
      respond to this therapy. Thus, the search for biomarkers of clinical response to 
      these agents is currently highly active. Our aim is to analyze the number and 
      distribution of circulating monocytes, and of their CD14(+)highCD16(-), 
      CD14(+)highCD16(+) and CD14(+)lowCD16+ subsets in methotrexate (MTX) non-responder 
      patients with RA, and to determine their value in predicting the clinical 
      response to adalimumab plus MTX treatment. METHODS: This prospective work 
      investigated the number of circulating monocytes, and of their CD14(+)highCD16(-), 
      CD14(+)highCD16(+) and CD14(+)lowCD16(+) subsets, in 35 MTX non-responder patients with 
      RA before and after three and six months of anti-TNFalpha treatment using 
      multiparametric flow cytometry. The number of circulating monocytes in an age- 
      and sex-matched healthy population was monitored as a control. RESULTS: 
      Non-responder patients with RA show an increased number of monocytes and of their 
      CD14(+)highCD16(-), CD14(+)highCD16(+) and CD14(+)lowCD16(+) subsets after three months of 
      adalimumab plus MTX treatment that remained significantly increased at six 
      months. In contrast, significant normalization of the numbers of circulating 
      monocytes was found in responders at three months of adalimumab plus MTX 
      treatment that lasts up to six months. CX3CR1 expression is increased in 
      monocytes in non-responders. At three months of anti-TNFalpha treatment the number of 
      circulating monocytes and their subsets was associated with at least 80% 
      sensitivity, 84% specificity and an 86% positive predictive value (PPV) in terms 
      of discriminating between eventual early responders and non-responders. 
      CONCLUSIONS: The absolute number of circulating monocytes and of their 
      CD14(+)highCD16(-), CD14(+)highCD16(+) and CD14(+)lowCD16(+) subsets at three months of 
      adalimumab plus MTX treatment, have a predictive value (with high specificity and 
      sensitivity) in terms of the clinical response after six months of anti-TNFalpha 
      treatment in patients with RA.
FAU - Chara, Luis
AU  - Chara L
FAU - Sanchez-Atrio, Ana
AU  - Sanchez-Atrio A
FAU - Perez, Ana
AU  - Perez A
FAU - Cuende, Eduardo
AU  - Cuende E
FAU - Albarran, Fernando
AU  - Albarran F
FAU - Turrion, Ana
AU  - Turrion A
FAU - Chevarria, Julio
AU  - Chevarria J
FAU - Sanchez, Miguel A
AU  - Sanchez MA
FAU - Monserrat, Jorge
AU  - Monserrat J
FAU - de la Hera, Antonio
AU  - de la Hera A
FAU - Prieto, Alfredo
AU  - Prieto A
FAU - Sanz, Ignacio
AU  - Sanz I
FAU - Diaz, David
AU  - Diaz D
FAU - Alvarez-Mon, Melchor
AU  - Alvarez-Mon M
LA  - eng
GR  - R37 AI049660/AI/NIAID NIH HHS/United States
GR  - U19 AI056390/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120727
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Antirheumatic Agents/*administration & dosage
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Biomarkers/blood
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Methotrexate/*administration & dosage
MH  - Middle Aged
MH  - Monocytes/*drug effects/metabolism
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC3580569
EDAT- 2012/07/31 06:00
MHDA- 2015/06/24 06:00
PMCR- 2012/07/27
CRDT- 2012/07/31 06:00
PHST- 2012/02/24 00:00 [received]
PHST- 2012/07/27 00:00 [accepted]
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
PHST- 2012/07/27 00:00 [pmc-release]
AID - ar3928 [pii]
AID - 10.1186/ar3928 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2012 Jul 27;14(4):R175. doi: 10.1186/ar3928.